within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BX04_Relugolix;

model Relugolix
  extends Pharmacolibrary.Drugs.ATC.L.L02BX04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L02BX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Relugolix is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat advanced prostate cancer and uterine fibroids. It works by reducing the amounts of luteinizing hormone and follicle-stimulating hormone, thereby lowering testosterone or estrogen levels. It is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in adult males with advanced prostate cancer after multiple oral doses. Parameters are based on data from healthy adult volunteers and prostate cancer patients.</p><h4>References</h4><ol><li><p>George, DJ, et al., &amp; Shore, ND (2023). Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. <i>Clinical genitourinary cancer</i> 21(3) 383–392.e2. DOI:<a href=\"https://doi.org/10.1016/j.clgc.2023.03.009\">10.1016/j.clgc.2023.03.009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37062659/\">https://pubmed.ncbi.nlm.nih.gov/37062659</a></p></li><li><p>Barretta, M, et al., &amp; Grandi, G (2024). The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications. <i>Expert opinion on drug metabolism &amp; toxicology</i> None 1–13. DOI:<a href=\"https://doi.org/10.1080/17425255.2024.2441981\">10.1080/17425255.2024.2441981</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39666595/\">https://pubmed.ncbi.nlm.nih.gov/39666595</a></p></li><li><p>Hafron, J, et al., &amp; Pruett, J (2023). Adherence to Hormonal Therapies in Prostate Cancer. <i>Urology practice</i> 10(6) 540–546. DOI:<a href=\"https://doi.org/10.1097/UPJ.0000000000000445\">10.1097/UPJ.0000000000000445</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37647139/\">https://pubmed.ncbi.nlm.nih.gov/37647139</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Relugolix;
